Drug interactions
Buprenorphine subdermal implant + Eribulin
Severity: Moderate
Buprenorphine subdermal implant and Eribulin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Buprenorphine can prolong the QT interval, though effects at implant exposures are modest, and eribulin has a similar effect. Combined use may add slightly to arrhythmia risk, especially with other risk factors.
What this interaction means in plain words
Buprenorphine subdermal implant and Eribulin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Additive pharmacodynamic effect on cardiac repolarization (QT prolongation).
What to do
Obtain a baseline ECG and correct electrolyte abnormalities. Repeat ECG monitoring during eribulin cycles in patients with cardiac risk factors.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine subdermal implant and Eribulin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Eribulin
Frequently asked questions
Can I take Buprenorphine subdermal implant with Eribulin?
MediHelp rates the interaction as moderate. Buprenorphine subdermal implant and Eribulin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Buprenorphine can prolong the QT interval, though effects at implant exposures are modest, and eribulin has a similar effect. Combined use may add slightly to arrhythmia risk, especially with other risk factors.
How serious is the interaction between Buprenorphine subdermal implant and Eribulin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline ECG and correct electrolyte abnormalities. Repeat ECG monitoring during eribulin cycles in patients with cardiac risk factors.
What other medicines interact with Eribulin?
MediHelp also lists interactions of Eribulin with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Eribulin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
